Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Basevi (2012)
Standards of Medical Care in Diabetes—2013Diabetes Care, 36
R. Huijgen, E. Abbink, E. Bruckert, A. Stalenhoef, B. Imholz, P. Durrington, M. Trip, M. Eriksson, F. Visseren, J. Schaefer, J. Kastelein (2010)
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.Clinical therapeutics, 32 4
M. Chapman (2006)
Review: Fibrates: therapeutic reviewThe British Journal of Diabetes & Vascular Disease, 6
M. Bożentowicz-Wikarek, P. Kocełak, M. Smertka, M. Olszanecka-Glinianowicz, J. Chudek (2012)
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis — guidelines vs. realityPharmacological Reports, 64
Matthew Silva, Michele Matthews, Courtney Jarvis, Nicole Nolan, P. Belliveau, Michael Malloy, P. Gandhi (2007)
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.Clinical therapeutics, 29 2
William Boden, J. Probstfield, Todd Anderson, B. Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub (2011)
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.The New England journal of medicine, 365 24
J. Kane, M. Malloy, P. Tun, N. Phillips, D. Freedman, M. Williams, J. Rowe, R. Havel (1981)
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.The New England journal of medicine, 304 5
(2012)
The effect of colesevelam and niacin on low-density lipoprotein cholesterol and plasma glucose (abstr.)Circulation., 126
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
R. Knopp, Christine Tsunehara, B. Retzlaff, B. Fish, Hien Nguyen, S. Anderson, Thuy Nguyen (2006)
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.Metabolism: clinical and experimental, 55 12
J. Mckenney, Michael Jones, Stacey Abby (2005)
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemiaCurrent Medical Research and Opinion, 21
J. Armitage, Louise Bowman, K. Wallendszus, R. Bulbulia, Kazem Rahimi, R. Haynes, S. Parish, R. Peto, R. Collins (2010)
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialLancet, 376
D. Waters, J. Ho, S. Boekholdt, D. Demicco, J. Kastelein, Michael Messig, A. Breazna, T. Pedersen (2012)
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.Journal of the American College of Cardiology, 61 2
S. Cham, Marcella Evans, J. Denenberg, B. Golomb (2010)
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 PatientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30
J. Ryan, A. Jain (1972)
The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a long-term controlled study.The Journal of clinical pharmacology and new drugs, 12 7
D. Hunninghake, W. Insull, P. Toth, D. Davidson, J. Donovan, S. Burke (2001)
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.Atherosclerosis, 158 2
C. Glueck, S. Ford, D. Scheel, P. Steiner (1972)
Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia.JAMA, 222 6
Mukul Sharma, M. Ansari, A. Abou-Setta, K. Soares-Weiser, T. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, D. Moher (2009)
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for DyslipidemiaAnnals of Internal Medicine, 151
H. Bays, M. Davidson, Michael Jones, Stacey Abby (2006)
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.The American journal of cardiology, 97 8
Fred Kummerow (1993)
Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.Journal of the American College of Nutrition, 12 1
K. Kotseva, D. Wood, G. Backer, D. Bacquer, K. Pyörälä, U. Keil (2009)
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countriesThe Lancet, 373
Jennifer Robinson, C. Ballantyne, W. Hsueh, J. Rosen, Jianxin Lin, Arvind Shah, R. Lowe, M. Hanson, A. Tershakovec (2011)
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from thJournal of clinical lipidology, 5 6
Ž. Reiner (2010)
Combined therapy in the treatment of dyslipidemiaFundamental & Clinical Pharmacology, 24
Andrew Moore, B. Phan, C. Challender, Jayne Williamson, S. Marcovina, X. Zhao (2007)
Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease.Journal of clinical lipidology, 1 6
J. Donovan, J. Kisicki, M. Stiles, W. Tracewell, S. Burke (2002)
Effect of Colesevelam on Lovastatin PharmacokineticsAnnals of Pharmacotherapy, 36
(2008)
Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism
V. Basevi, S. Mario, Cristina Morciano, Francesco Nonino, Nicola Magrini (2011)
Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61Diabetes Care, 34
H. Casdorph (1967)
Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin.California medicine, 106 4
A. Egan, E. Colman (2011)
Weighing the benefits of high-dose simvastatin against the risk of myopathy.The New England journal of medicine, 365 4
B. Angelin, M. Eriksson, K. Einarsson (1986)
Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid compositionEuropean Journal of Clinical Investigation, 16
J. Donovan, D. Stypinski, M. Stiles, T. Olson, S. Burke (2000)
Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering AgentCardiovascular Drugs and Therapy, 14
S. Forland, Y. Feng, Ralph Cutler (1990)
Apparent Reduced Absorption of Gemfibrozil When Given with ColestipolThe Journal of Clinical Pharmacology, 30
(2012)
The effect of colesevelam and niacin on low-density lipoprotein cholesterol and plasma glucose (abstr.). Circulation
C. Gherondache, G. Pincus (1964)
METABOLIC CHANGES INDUCED IN ELDERLY PATIENTS WITH A CHOLESTEROL LOWERING RESIN, CHOLESTYRAMINE.Metabolism: clinical and experimental, 13
(2013)
Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survivalDiabetes Care., 36
(1988)
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsArch Intern Med, 148
N. Zaharan, David Williams, K. Bennett (2013)
Statins and risk of treated incident diabetes in a primary care population.British journal of clinical pharmacology, 75 4
N. Sattar, D. Preiss, H. Murray (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 375
M. Davidson, P. Toth, S. Weiss, J. Mckenney, D. Hunninghake, J. Isaacsohn, J. Donovan, S. Burke (2001)
Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemiaClinical Cardiology, 24
(2002)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation, 106
M. Florentin, E. Liberopoulos, C. Rizos, A. Kei, G. Liamis, M. Kostapanos, M. Elisaf (2013)
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.Metabolic syndrome and related disorders, 11 3
K. Brown, I. Armstrong, Antonia Wang, J. Walker, R. Noveck, D. Swearingen, M. Allison, J. Kissling, J. Kisicki, D. Salazar (2010)
Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and GlyburideThe Journal of Clinical Pharmacology, 50
Sami Hashim, T. Itallie (1965)
CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES.JAMA, 192
Ling He, Prachi Wickremasingha, James Lee, B. Tao, J. Mendell-Harary, J. Walker, D. Wight (2014)
The effects of colesevelam HCl on the single‐dose pharmacokinetics of glimepiride, extended‐release glipizide, and olmesartan medoxomilThe Journal of Clinical Pharmacology, 54
P. Toth (2012)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyYearbook of Medicine, 2012
Howard Knapp, Helmut Schrott, Patrick Ma, Robert Knopp, Bruce Chin, J. Gaziano, Joanne Donovan, Steven Burke, M. Davidson (2001)
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.The American journal of medicine, 110 5
R. Renfrew (1984)
Lipid Research Clinics Program.JAMA, 252 18
(2013)
Treatment of HDL to Reduce the Incidence of Vascular Events)
I. Mansi, C. Frei, M. Pugh, Una Makris, E. Mortensen (2013)
Statins and musculoskeletal conditions, arthropathies, and injuries.JAMA internal medicine, 173 14
Tuart, C. M., Obbe, Hristopher, I. G., Eter, M. W., Acfarlane, Ames, M. H, Illop, P. J., Ackard (2000)
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
V. Fonseca, J. Rosenstock, Antonia Wang, K. Truitt, Michael Jones (2008)
Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based TherapyDiabetes Care, 31
Scott Grundy, J. Cleeman, C. Merz, H. Brewer, Luther Clark, Donald Hunninghake, Richard Pasternak, Sidney Smith, Neil Stone (2004)
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation: Journal of the American Heart Association, 110
Scandinavian Group (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 344
G. Danaei, Luis Rodríguez, O. Cantero, M. Hernán (2013)
An analysis of electronic medical records to evaluate possible bias due to differential survival
W. Taylor, N. Unwin (2009)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National
A. Catapano, Željko Reiner, G. Backer, I. Graham, M. Taskinen, O. Wiklund, S. Agewall, E. Alegrı́a, M. Chapman, P. Durrington, S. Erdine, J. Halcox, Richard Hobbs, J. Kjekshus, P. Filardi, G. Riccardi, R. Storey, D. Wood, P. Kolh (2011)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).European heart journal, 32 14
D. Preiss, S. Seshasai, P. Welsh, S. Murphy, J. Ho, D. Waters, D. Demicco, P. Barter, C. Cannon, M. Sabatine, E. Braunwald, J. Kastelein, J. Lemos, M. Blazing, T. Pedersen, M. Tikkanen, N. Sattar, K. Ray (2011)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.JAMA, 305 24
(2011)
Eur Heart J
H. Bays, J. Rhyne, Stacey Abby, Y. Lai, Michael Jones (2006)
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe*Current Medical Research and Opinion, 22
T. Parkinson, K. Gundersen, N. Nelson (1970)
Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man.Atherosclerosis, 11 3
(2008)
Nwose treated with metformin: glucose and lipid effects
B. Mihaylova, J. Emberson, L. Blackwell, Anthony Keech, J. Simes, Elizabeth Barnes, M. Voysey, Alastair Gray, R. Collins, C. Baigent (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsLancet, 380
A. Mammen, A. Amato (2010)
Statin myopathy: a review of recent progressCurrent Opinion in Rheumatology, 22
Ling He, Prachi Wickremasingha, James Lee, B. Tao, J. Mendell-Harary, J. Walker, D. Wight (2014)
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.Diabetes research and clinical practice, 104 3
K. Kotseva, D. Wood, G. Backer, D. Bacquer, K. Pyörälä, Ž. Reiner, U. Keil (2010)
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countriesEuropean Journal of Preventive Cardiology, 17
Michael Jones, B. Baker, P. Mathew (2004)
Effect of Colesevelam HCl on Single-Dose Fenofibrate PharmacokineticsClinical Pharmacokinetics, 43
R. Goldberg, V. Fonseca, K. Truitt, Michael Jones (2008)
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.Archives of internal medicine, 168 14
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
(1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.JAMA, 251 3
T. Kosoglou (2003)
P2367 Effects of selected drugs on exposure to ezetimibeEuropean Heart Journal, 24
(2010)
J Clin Pharmacol
Alberico Catapano, Željko Reiner, Guy Backer, Ian Graham, M. Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M. Chapman, P. Durrington, S. Erdine, Julian Halcox, Richard Hobbs, J. Kjekshus, Pasquale Filardi, G. Riccardi, Robert Storey, David Wood (2011)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis, 217 Suppl 1
A. Yan, R. Yan, M. Tan, D. Hackam, K. Leblanc, H. Kertland, J. Tsang, Shahin Jaffer, M. Kates, Lawrence Leiter, D. Fitchett, A. Langer, S. Goodman (2006)
Contemporary management of dyslipidemia in high-risk patients: targets still not met.The American journal of medicine, 119 8
S. Grundy, D. Becker, L. Clark, R. Cooper, M. Denke, James Howard, D. Hunninghake, D. Illingworth, R. Luepker, P. Mcbride, J. Mckenney, R. Pasternak, N. Stone, L. Horn, H. Brewer, J. Cleeman, N. Ernst, D. Gordon, D. Levy, B. Rifkind, J. Rossouw, P. Savage, S. Haffner, D. Orloff, M. Proschan, J. Schwartz, C. Sempos, Susan Shero, Elaine Murray, Susan Keller, Angela Jehle, T. Ganiats, Gary Graham (2015)
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
H. Smith, L. Jokubaitis, A. Troendle, D. Hwang, W. Robinson (1993)
Pharmacokinetics of fluvastatin and specific drug interactions.American journal of hypertension, 6 11 Pt 2
S. Grundy, J. Cleeman, C Noel, B. Merz, H Brewer, L. Clark, D. Hunninghake, R. Pasternak, Sidney Smith, N. Stone (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.Journal of the American College of Cardiology, 44 3
Bile Acid Sequestrant-Based Combination Therapy
I. Jialal, Stacey Abby, S. Misir, S. Nagendran (2009)
Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.Metabolic syndrome and related disorders, 7 3
A. Nakai, M. Nishikata, K. Matsuyama, M. Ichikawa (1996)
Drug interaction between simvastatin and cholestyramine in vitro and in vivo.Biological & pharmaceutical bulletin, 19 9
C. Becker (1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.JAMA, 251 3
T. Pearson, I. Laurora, H. Chu, S. Kafonek (2000)
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Archives of internal medicine, 160 4
J. Spence (2013)
Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
A. Pandor, R. Ara, I. Tumur, A. Wilkinson, S. Paisley, A. Duenas, P. Durrington, J. Chilcott (2009)
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trialsJournal of Internal Medicine, 265
H. Bays, R. Goldberg, K. Truitt, Michael Jones (2008)
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.Archives of internal medicine, 168 18
N. Rautio, J. Jokelainen, H. Oksa, T. Saaristo, Markku Peltonen, M. Vanhala, H. Puolijoki, L. Moilanen, J. Tuomilehto, S. Keinänen-Kiukaanniemi, M. Uusitupa (2012)
Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D projectBMJ Open, 2
Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy for reducing LDL-C levels because of their potency and their remarkable record of successful outcomes studies. Nevertheless, a substantial proportion of patients do not achieve LDL-C goals with statin monotherapy. In addition, because of adverse effects (primarily myopathy), some patients may be unwilling to use or unable to tolerate statin therapy at all or may not tolerate a full therapeutic statin dose. Also, statins may increase risk of new-onset diabetes in patients at high risk for diabetes. Thus, there remains a need for other lipid-lowering drugs to be used in combination with or in place of statins. The purpose of this article is to review available data from the literature on the use of colesevelam, a second-generation bile acid sequestrant, in combination with other lipid-lowering agents. Colesevelam has been studied in combination with statins, niacin, fibrates, and ezetimibe (including some three-drug combinations). An additive reduction in LDL-C was seen with all combinations. Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Triglyceride levels remained relatively unchanged when colesevelam was combined with statins, fibrates, ezetimibe, or statin plus ezetimibe, and decreased with the triple combination of colesevelam, statin, and niacin. Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. Colesevelam was generally well tolerated when added to other lipid-lowering therapies in clinical trials, with gastrointestinal effects such as constipation being the predominant adverse events. Since colesevelam is not absorbed and works primarily in the intestine, it has a low potential for systemic metabolic drug–drug interactions with other drugs. Colesevelam has been shown to not interact with the lipid-lowering drugs lovastatin and fenofibrate; where interaction may be anticipated, separating dosing times by 4 h reduces the impact of any interaction. Available data confirms that colesevelam has additive cholesterol-lowering effects when used in combination with other lipid-lowering therapies. Furthermore, in some patient populations, the additional glucose-lowering effect of colesevelam may be beneficial in offsetting hyperglycemic effects of other lipid-lowering drugs.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 3, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.